We propose that in advanced prostate cancer, miR-410 upregulation leads to PRKD1 inhibition that promotes EMT, likely via non-phosphorylation of SNAIL and other mechanisms such as β-catenin activation [46]. The gene discussed is PRKD1; the disease is prostate carcinoma.